Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
SBUX Starbucks Corp
HYLN Hyliion Holdings Corp
NIO NIO Inc
F Ford Motor Co
GM General Motors Co
PG Procter & Gamble Co
GE General Electric Co
DEO Diageo PLC
KO Coca-Cola Co
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Closing Price
$58.15
Day's Change
-0.38 (-0.65%)
Bid
--
Ask
--
B/A Size
--
Day's High
58.58
Day's Low
57.18
Volume
(Average)
Volume:
11,871,686

10-day average volume:
12,568,205
11,871,686

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Immunomedics, Inc. - IMMU

8:00 pm ET September 18, 2020 (PR Newswire) Print

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Immunomedics, Inc. ("Immunomedics" or the "Company") (IMMU) relating to the sale of the Company to Gilead Sciences, Inc. Under the terms of the agreement, Immunomedics shareholders are anticipated to receive $88.00 per share for each share of Immunomedics they own.

https://mma.prnewswire.com/media/443626/Monteverde_Associates_PC_Logo.jpg

Click here for more information: https://www.monteverdelaw.com/case/immunomedics-inc. It is free and there is no cost or obligation to you.

The investigation focuses on whether Immunomedics and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company's stockholders by 1) failing to conduct a fair process, 2) whether and by how much this proposed transaction undervalues the Company and 3) failing to disclose all material information.

About Monteverde & Associates PC

We are a national class action securities litigation law firm that has recovered millions of dollars and is committed to protecting shareholders from corporate wrongdoing. Our lawyers have significant experience litigating Mergers & Acquisitions and Securities Class Actions. Mr. Monteverde is recognized by Super Lawyers as a Rising Star in Securities Litigation in 2013, 2017-2019, an award given to less than 2.5% of attorneys in a particular field. He has also been selected by Martindale-Hubbell as a 2017-2019 Top Rated Lawyer. Our firm's recent successes include changing the law in a significant victory that lowered the standard of liability under Section 14(e) of the Exchange Act in the Ninth Circuit. Thereafter, our firm successfully preserved this victory by obtaining dismissal of a writ of certiorari as improvidently granted at the United States Supreme Court. Emulex Corp. v. Varjabedian, 139 S. Ct. 1407 (2019). Also, in 2019 we recovered or secured six cash common funds for shareholders in mergers & acquisitions class action cases.

If you own common stock in Immunomedics, Inc. and wish to obtain additional information and protect your investments free of charge, please visit our website or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.

Contact:Juan E. Monteverde, Esq.MONTEVERDE & ASSOCIATES PCThe Empire State Building 350 Fifth Ave. Suite 4405New York, NY 10118United States of Americajmonteverde@monteverdelaw.com Tel: (212) 971-1341

Attorney Advertising. (C) 2020 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.

https://c212.net/c/img/favicon.png?sn=DC29002&sd=2020-09-18

View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-monteverde--associates-pc-announces-an-investigation-of-immunomedics-inc--immu-301134120.html

SOURCE Monteverde & Associates PC

https://rt.prnewswire.com/rt.gif?NewsItemId=DC29002&Transmission_Id=202009182000PR_NEWS_USPR_____DC29002&DateId=20200918

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.